Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Debt Ratio (2016 - 2021)

Historic Debt Ratio for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Q1 2021 value amounting to 0.0.

  • Lineage Cell Therapeutics' Debt Ratio changed N/A to 0.0 in Q1 2021 from the same period last year, while for Mar 2021 it was 0.0, marking a year-over-year change of. This contributed to the annual value of 0.0 for FY2020, which is N/A changed from last year.
  • As of Q1 2021, Lineage Cell Therapeutics' Debt Ratio stood at 0.0.
  • Over the past 5 years, Lineage Cell Therapeutics' Debt Ratio peaked at 0.01 during Q3 2020, and registered a low of 0.0 during Q4 2017.
  • Its 3-year average for Debt Ratio is 0.0, with a median of 0.0 in 2021.
  • Within the past 5 years, the most significant YoY rise in Lineage Cell Therapeutics' Debt Ratio was 7037.06% (2017), while the steepest drop was 8765.55% (2017).
  • Quarter analysis of 3 years shows Lineage Cell Therapeutics' Debt Ratio stood at 0.0 in 2017, then skyrocketed by 4562.96% to 0.0 in 2020, then dropped by 15.62% to 0.0 in 2021.
  • Its last three reported values are 0.0 in Q1 2021, 0.0 for Q4 2020, and 0.01 during Q3 2020.